Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

IGC Pharma Q3 2026 Results: Net Loss of $2.05M, Loss Widens

IGC Pharma, Inc. reported a net loss of $7.38 million for the nine months ended September 30, 2026, compared to a $4.62 million loss in the prior year period. While revenue increased slightly to $910,000, the company's operating loss widened due to higher research and development and administrative expenses related to its clinical trials.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.30.2
Gross profit0.10.1
Profit before tax-2.0-1.8
Net income-2.0-1.8
EPS (diluted, $ a share)$-0.02$-0.02

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+71.7%
Gross margin18.6%
Source

10-Q filed with the SEC, NYSE: IGC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

IGC Pharma, Inc.: key numbers

Share price
$0.1750Close, Nov 16
Market cap
$20.4M
Shares outstanding
116.69MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.